Adaptimmune Therapeutics News Headlines (NASDAQ:ADAP)

$1.77
+0.02 (+1.14 %)
(As of 09/22/2019 04:00 PM ET)
Today's Range
$1.6899
Now: $1.77
$1.78
50-Day Range
$1.41
MA: $1.78
$3.10
52-Week Range
$1.37
Now: $1.77
$14.54
Volume140,330 shs
Average Volume240,281 shs
Market Capitalization$185.30 million
P/E RatioN/A
Dividend YieldN/A
Beta1.79

Headlines

Adaptimmune Therapeutics (NASDAQ ADAP) News Headlines

Source:
DateHeadline
Synovial Sarcoma Treatment Sales Market By Current Industry Status,Growth Opportunities, Top Key Players, Target Audience And Forecast To 2022Synovial Sarcoma Treatment Sales Market By Current Industry Status,Growth Opportunities, Top Key Players, Target Audience And Forecast To 2022
www.marketwatch.com - September 21 at 5:22 AM
Does The Adaptimmune Therapeutics plc (NASDAQ:ADAP) Share Price Fall With The Market?Does The Adaptimmune Therapeutics plc (NASDAQ:ADAP) Share Price Fall With The Market?
finance.yahoo.com - September 16 at 9:01 AM
Philadelphia Immuno-oncology company Imvax hires CEOPhiladelphia Immuno-oncology company Imvax hires CEO
www.bizjournals.com - September 10 at 5:25 AM
Adaptimmunes SPEAR T-cells targeting MAGE-A4 an Orphan Drug in U.S.Adaptimmune's SPEAR T-cells targeting MAGE-A4 an Orphan Drug in U.S.
seekingalpha.com - September 10 at 5:25 AM
United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4
finance.yahoo.com - September 10 at 5:25 AM
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Receives Consensus Recommendation of "Hold" from BrokeragesAdaptimmune Therapeutics PLC - (NASDAQ:ADAP) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 7 at 12:47 PM
$4.25 Million in Sales Expected for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) This Quarter$4.25 Million in Sales Expected for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) This Quarter
www.americanbankingnews.com - September 5 at 4:02 AM
Financial Review: Biogen (NASDAQ:BIIB) versus Adaptimmune Therapeutics (NASDAQ:ADAP)Financial Review: Biogen (NASDAQ:BIIB) versus Adaptimmune Therapeutics (NASDAQ:ADAP)
www.americanbankingnews.com - September 4 at 4:16 AM
Zacks: Analysts Anticipate Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Will Post Earnings of -$0.33 Per ShareZacks: Analysts Anticipate Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Will Post Earnings of -$0.33 Per Share
www.americanbankingnews.com - September 3 at 10:17 AM
BRIEF-Adaptimmune And Noile-Immune Announce Pact To Develop Spear T-Cell Products For CancerBRIEF-Adaptimmune And Noile-Immune Announce Pact To Develop Spear T-Cell Products For Cancer
www.msn.com - August 28 at 12:31 PM
Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patientsAdaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients
finance.yahoo.com - August 27 at 9:04 AM
Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical OfficerAllogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer
www.marketwatch.com - August 5 at 10:59 AM
Edited Transcript of ADAP earnings conference call or presentation 1-Aug-19 12:00pm GMTEdited Transcript of ADAP earnings conference call or presentation 1-Aug-19 12:00pm GMT
finance.yahoo.com - August 4 at 7:25 PM
Adaptimmune Therapeutics plc (ADAP) CEO James Noble on Q2 2019 Results - Earnings Call TranscriptAdaptimmune Therapeutics plc (ADAP) CEO James Noble on Q2 2019 Results - Earnings Call Transcript
seekingalpha.com - August 3 at 6:42 PM
Adaptimmune Reports Second Quarter 2019 Financial Results and Business UpdateAdaptimmune Reports Second Quarter 2019 Financial Results and Business Update
finance.yahoo.com - August 1 at 10:25 AM
New Executive Team Announced at AdaptimmuneNew Executive Team Announced at Adaptimmune
finance.yahoo.com - August 1 at 10:25 AM
Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019
finance.yahoo.com - July 29 at 11:43 PM
Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLSAdaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
finance.yahoo.com - July 25 at 11:32 AM
Adaptimmune up 10% on promise of low-dose radiation to improve SPEAR T-cell therapyAdaptimmune up 10% on promise of low-dose radiation to improve SPEAR T-cell therapy
seekingalpha.com - July 22 at 7:13 PM
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer CenterAdaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
finance.yahoo.com - July 22 at 8:55 AM
How Should Investors Feel About Adaptimmune Therapeutics plc's (NASDAQ:ADAP) CEO Pay?How Should Investors Feel About Adaptimmune Therapeutics plc's (NASDAQ:ADAP) CEO Pay?
finance.yahoo.com - July 18 at 6:50 PM
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor ResponsesAdaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses
finance.yahoo.com - July 18 at 9:07 AM
Adaptimmune Therapeutics PLC (ADAP) Upgraded to Strong Buy: Heres WhyAdaptimmune Therapeutics PLC (ADAP) Upgraded to Strong Buy: Here's Why
finance.yahoo.com - July 9 at 6:23 PM
Synovial Sarcoma Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug DevelopersSynovial Sarcoma Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers
www.marketwatch.com - July 2 at 6:20 PM
Is Adaptimmune Therapeutics plc (ADAP) Going to Burn These Hedge Funds?Is Adaptimmune Therapeutics plc (ADAP) Going to Burn These Hedge Funds?
finance.yahoo.com - June 30 at 8:37 AM
New chief at AdaptimmuneNew chief at Adaptimmune
seekingalpha.com - June 27 at 6:27 PM
5 More Stocks Priced Under $10 With Massive Implied Upside5 More Stocks Priced Under $10 With Massive Implied Upside
www.msn.com - June 1 at 8:45 AM
Those Who Purchased Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Have A 72% Loss To Show For ItThose Who Purchased Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Have A 72% Loss To Show For It
finance.yahoo.com - May 28 at 6:02 PM
Here’s What Hedge Funds Think About Adaptimmune Therapeutics plc (ADP)Here’s What Hedge Funds Think About Adaptimmune Therapeutics plc (ADP)
finance.yahoo.com - May 10 at 8:47 AM
Adaptimmune up 6% premarket on positive ADP-A2M4 data in cancerAdaptimmune up 6% premarket on positive ADP-A2M4 data in cancer
seekingalpha.com - May 6 at 7:23 PM
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid TumorsSignificant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
finance.yahoo.com - May 6 at 8:42 AM
Adaptimmune Reports First Quarter 2019 Financial ResultsAdaptimmune Reports First Quarter 2019 Financial Results
finance.yahoo.com - May 6 at 8:42 AM
Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT MeetingAdaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting
finance.yahoo.com - May 2 at 8:47 AM
Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019
finance.yahoo.com - May 1 at 8:34 AM
Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT MeetingAdaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting
finance.yahoo.com - April 18 at 7:14 PM
Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) MeetingAdaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
finance.yahoo.com - April 2 at 9:25 AM
Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual MeetingAdaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 1 at 8:51 AM
Does Adaptimmune Therapeutics plc (NASDAQ:ADAP) Have A Particularly Volatile Share Price?Does Adaptimmune Therapeutics plc (NASDAQ:ADAP) Have A Particularly Volatile Share Price?
finance.yahoo.com - March 15 at 7:08 PM
Edited Transcript of ADAP earnings conference call or presentation 27-Feb-19 1:00pm GMTEdited Transcript of ADAP earnings conference call or presentation 27-Feb-19 1:00pm GMT
finance.yahoo.com - February 28 at 8:51 AM
CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business UpdateCORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
globenewswire.com - February 27 at 7:02 PM
Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business UpdateAdaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
finance.yahoo.com - February 27 at 8:43 AM
Should You Worry About Adaptimmune Therapeutics plc’s (NASDAQ:ADAP) CEO Salary Level?Should You Worry About Adaptimmune Therapeutics plc’s (NASDAQ:ADAP) CEO Salary Level?
finance.yahoo.com - February 7 at 6:24 PM
Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
finance.yahoo.com - February 7 at 8:40 AM
The Unknown Biotech Play that Could Deliver 400% Returns, or Much MoreThe Unknown Biotech Play that Could Deliver 400% Returns, or Much More
www.marketwatch.com - February 1 at 8:50 AM
Adaptimmune Therapeutics PLC (ADAP) Upgraded to Buy: Heres What You Should KnowAdaptimmune Therapeutics PLC (ADAP) Upgraded to Buy: Here's What You Should Know
finance.yahoo.com - January 28 at 6:05 PM
Adaptimmune Therapeutics PLC (ADAP) Upgraded to Buy: Here's What You Should KnowAdaptimmune Therapeutics PLC (ADAP) Upgraded to Buy: Here's What You Should Know
finance.yahoo.com - January 28 at 6:05 PM
Adaptimmune Therapeutics PLC (ADAP)Adaptimmune Therapeutics PLC (ADAP)
www.zacks.com - January 8 at 6:03 PM
Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety ReviewsDose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
finance.yahoo.com - January 7 at 8:32 AM
What Percentage Of Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Do Insiders Own?What Percentage Of Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Do Insiders Own?
finance.yahoo.com - January 2 at 5:17 PM
Adaptimmune tech chief to depart next month; shares down 12%Adaptimmune tech chief to depart next month; shares down 12%
seekingalpha.com - December 12 at 4:03 PM
This page was last updated on 9/22/2019 by MarketBeat.com Staff

Featured Article: Dead Cat Bounce

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel